China News Service, Guangzhou, November 28 (Cai Minjie) The 2020 Precision Medicine Conference hosted by the Guangdong Society of Precision Medicine Applications is being held in Guangzhou.
The "Rainbow Project", a large-scale public welfare health intervention project led by Hou Jinlin, director of the Department of Infectious Medicine, Nanfang Hospital of Southern Medical University, was officially launched at the meeting.
The project will organize 1,000 medical institutions across the country to conduct liver cancer risk assessment for 1 million patients with chronic liver disease, and help early screening and diagnosis of liver cancer.
The World Health Organization issued a global strategy for the prevention and treatment of viral hepatitis four years ago, and proposed that by 2030, the rate of new viral hepatitis infections should be reduced by 90% and the mortality rate related to viral hepatitis should be reduced by 65%.
In the Mainland, liver cancer is the main cause of death among patients with viral hepatitis. The death toll from liver cancer reaches more than 300,000 every year, bringing a huge medical burden to the country.
Among the hospitalized patients in Guangdong Province from 2013 to 2019, there were 170,000 liver cancer patients, 80% of which were advanced liver cancer.
In response to this situation, Hou Jinlin's major national science and technology research project, through international cooperation, lasted more than 10 years, constructed a long-term follow-up cohort of 17,374 patients with chronic liver disease including 11 prospective cohorts around the world, and created a long-term follow-up cohort suitable for various diseases. The predictive score (aMAP score) that can assess the risk of liver cancer in 5 years (hepatitis B, hepatitis C, fatty liver, etc.) and various races (Asian, Western, etc.).
The research results were officially published online in the Journal of Hepatology on July 20, 2020.
According to Hou Jinlin, after optimization, the aMAP score only needs to pass five common test indicators, including the patient's age, gender, platelet, albumin and bilirubin levels, to help doctors determine the possibility of liver cancer.
This model is not only applicable to large hospitals, but also to grassroots community health service centers.
It is understood that the aMAP score is 0-100 points, and patients are divided into low-risk group (0-50 points), medium-risk group (50-60 points) and high-risk group (60-100 points) according to the score.
"This is the first cross-disease, cross-ethnic chronic liver disease liver cancer prediction model, guiding all chronic liver disease populations to implement individualized liver cancer screening strategies and saving medical resources." Hou Jinlin said.
It is reported that the aMAP liver cancer risk scoring model has been made into a small program, and patients can input their own physical examination indicators for self-help liver cancer risk assessment, and then further seek doctors for treatment intervention, in order to increase the rate of early diagnosis of liver cancer.